These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1791319)

  • 1. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
    Masson P; Pålsson B; Andren-Sandberg A
    Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated trypsin inhibitor in pancreatic diseases.
    Aroasio E; Piantino P
    Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
    Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
    Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
    Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
    Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA 242 is a new tumor marker for pancreatic cancer.
    Röthlin MA; Joller H; Largiadèr F
    Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
    Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
    Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
    de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
    Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
    Catarino M; Conde R
    Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
    Piantino P; Arosaio E
    Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
    Jurkowska G; Kulpa J; Skrodzka D; Rogowski F
    Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
    Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
    Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions.
    Räty S; Sand J; Alfthan H; Haglund C; Nordback I
    J Gastrointest Surg; 2004; 8(5):569-74. PubMed ID: 15239993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA 494--a new tumor marker for the diagnosis of pancreatic cancer.
    Friess H; Büchler M; Auerbach B; Weber A; Malfertheiner P; Hammer K; Madry N; Greiner S; Bosslet K; Beger HG
    Int J Cancer; 1993 Mar; 53(5):759-63. PubMed ID: 8449599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-associated trypsin inhibitor and renal cell carcinoma.
    Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
    Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.